Dataset.
Supplements to: A naturalistic cohort study of first-episode schizophrenia spectrum disorder: a description of the early phase of illness in the PSYSCAN cohort
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/359900
Digital.CSIC. Repositorio Institucional del CSIC
- Slot, Margot I. E.
- van Hell, Hendrika H.
- Rossum, Inge Winter-van
- Dazzan, Paola
- Maat, Arija
- de Haan, Lieuwe
- Crespo-Facorro, Benedicto
- Glenthøj, Birte
- Lawrie, Stephen M.
- McDonald, Colm
- Gruber, Oliver
- van Amelsvoort, Thérèse
- Arango, Celso
- Kircher, Tilo
- Nelson, Barnaby
- Galderisi, Silvana
- Weiser, Mark
- Sachs, Gabriele
- Maatz, Anke
- Bressan, Rodrigo A.
- Kwon, Jun Soo
- Mizrahi, Romina
- McGuire, Philip
- Kahn, René S.
Suppl. Figure 1. Percentage of FES patients in symptomatic remission throughout the study., Suppl. Figure 2. Percentage of FES patients in functional remission throughout the study., Suppl. Figure 3. Clustered boxplot displaying the mean depression scores per time point (measured using the Hamilton Depression Rating Scale) in the subgroup meeting criteria for a depressive episode at baseline (assessed through the SCID-I) versus the subgroup without a depressive episode at baseline., Suppl. Table 1. Baseline demographics and clinical characteristics of study completers and drop-outs., Suppl. Table 2. Number of patients in symptomatic and functional remission throughout the period of follow-up., Suppl. Table 3. Generalized linear mixed models: pairwise contrasts for symptomatic and functional remission., Suppl. Table 4. Linear mixed models: estimated marginal means for PANSS, GAF, SOFAS, CGI, GF-S, GF-R and HAM-D., Suppl. Table 5. Linear mixed models: estimates of fixed effect time on PANSS, GAF, SOFAS, CGI, GF-S, GF-R and HAM-D., Suppl. Table 6. Number of patients admitted to the hospital since the previous visit due to psychotic symptoms and due to psychiatric reasons
in general., Suppl. Table 7. Substances used at least once in the past three months (WHO-ASSIST)., Suppl. Table 8. Number of patients reporting daily or almost daily substance use in the past three months, separated per time point and substance category (WHO-ASSIST)., Suppl. Table 9. Number of patients reporting daily or almost daily substance use in the past three months, separated for the group of symptomatic remitters and non-remitters at month 12., Suppl. Table 10. Baseline demographics and clinical characteristics of symptomatic remitters and non-remitters at month 12., Suppl. Table 11. Summary of sociodemographics and baseline clinical characteristics of FES participants, separated per country., Suppl. Table 12. Number of FES patients in symptomatic remission throughout the period of follow-up, separated
per country., Suppl. Table 13. Number of FES patients in functional remission throughout the period of follow-up, separated
per country., Suppl. Table 14. Number of FES patients admitted to the hospital for psychiatric reasons throughout the period
of follow-up, separated per country., Suppl. Table 15. Number of FES patients admitted to the hospital for psychosis throughout the period of follow-up, separated per country., Suppl. Table 16. Number of FES patients using antipsychotic medication throughout the period of follow-up,
separated per country., Suppl. Table 17. Overview of subjects not meeting eligibility criteria., Suppl. Table 18. Number of patients in symptomatic and functional remission throughout the period of follow-up when using alternative definitions., Suppl. Table 19. Generalized linear mixed models: pairwise contrasts for symptomatic and functional remission when using alternative definitions., Peer reviewed
DOI: http://hdl.handle.net/10261/359900
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/359900
HANDLE: http://hdl.handle.net/10261/359900
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/359900
Ver en: http://hdl.handle.net/10261/359900
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/359900
No hay resultados en la búsqueda
No hay resultados en la búsqueda
×
1 Versiones
1 Versiones
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/359900
Dataset. 2024
SUPPLEMENTS TO: A NATURALISTIC COHORT STUDY OF FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER: A DESCRIPTION OF THE EARLY PHASE OF ILLNESS IN THE PSYSCAN COHORT
Digital.CSIC. Repositorio Institucional del CSIC
- Slot, Margot I. E.
- van Hell, Hendrika H.
- Rossum, Inge Winter-van
- Dazzan, Paola
- Maat, Arija
- de Haan, Lieuwe
- Crespo-Facorro, Benedicto
- Glenthøj, Birte
- Lawrie, Stephen M.
- McDonald, Colm
- Gruber, Oliver
- van Amelsvoort, Thérèse
- Arango, Celso
- Kircher, Tilo
- Nelson, Barnaby
- Galderisi, Silvana
- Weiser, Mark
- Sachs, Gabriele
- Maatz, Anke
- Bressan, Rodrigo A.
- Kwon, Jun Soo
- Mizrahi, Romina
- McGuire, Philip
- Kahn, René S.
Suppl. Figure 1. Percentage of FES patients in symptomatic remission throughout the study., Suppl. Figure 2. Percentage of FES patients in functional remission throughout the study., Suppl. Figure 3. Clustered boxplot displaying the mean depression scores per time point (measured using the Hamilton Depression Rating Scale) in the subgroup meeting criteria for a depressive episode at baseline (assessed through the SCID-I) versus the subgroup without a depressive episode at baseline., Suppl. Table 1. Baseline demographics and clinical characteristics of study completers and drop-outs., Suppl. Table 2. Number of patients in symptomatic and functional remission throughout the period of follow-up., Suppl. Table 3. Generalized linear mixed models: pairwise contrasts for symptomatic and functional remission., Suppl. Table 4. Linear mixed models: estimated marginal means for PANSS, GAF, SOFAS, CGI, GF-S, GF-R and HAM-D., Suppl. Table 5. Linear mixed models: estimates of fixed effect time on PANSS, GAF, SOFAS, CGI, GF-S, GF-R and HAM-D., Suppl. Table 6. Number of patients admitted to the hospital since the previous visit due to psychotic symptoms and due to psychiatric reasons
in general., Suppl. Table 7. Substances used at least once in the past three months (WHO-ASSIST)., Suppl. Table 8. Number of patients reporting daily or almost daily substance use in the past three months, separated per time point and substance category (WHO-ASSIST)., Suppl. Table 9. Number of patients reporting daily or almost daily substance use in the past three months, separated for the group of symptomatic remitters and non-remitters at month 12., Suppl. Table 10. Baseline demographics and clinical characteristics of symptomatic remitters and non-remitters at month 12., Suppl. Table 11. Summary of sociodemographics and baseline clinical characteristics of FES participants, separated per country., Suppl. Table 12. Number of FES patients in symptomatic remission throughout the period of follow-up, separated
per country., Suppl. Table 13. Number of FES patients in functional remission throughout the period of follow-up, separated
per country., Suppl. Table 14. Number of FES patients admitted to the hospital for psychiatric reasons throughout the period
of follow-up, separated per country., Suppl. Table 15. Number of FES patients admitted to the hospital for psychosis throughout the period of follow-up, separated per country., Suppl. Table 16. Number of FES patients using antipsychotic medication throughout the period of follow-up,
separated per country., Suppl. Table 17. Overview of subjects not meeting eligibility criteria., Suppl. Table 18. Number of patients in symptomatic and functional remission throughout the period of follow-up when using alternative definitions., Suppl. Table 19. Generalized linear mixed models: pairwise contrasts for symptomatic and functional remission when using alternative definitions., Peer reviewed
There are no results for this search
1106